These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20919824)

  • 1. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
    Ströhlein MA; Heiss MM
    Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
    Jäger M; Schoberth A; Ruf P; Hess J; Hennig M; Schmalfeldt B; Wimberger P; Ströhlein M; Theissen B; Heiss MM; Lindhofer H
    Cancer Res; 2012 Jan; 72(1):24-32. PubMed ID: 22044753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.
    Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF
    Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.
    Goéré D; Gras-Chaput N; Aupérin A; Flament C; Mariette C; Glehen O; Zitvogel L; Elias D
    BMC Cancer; 2014 Mar; 14():148. PubMed ID: 24589307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer.
    Papanikolaou G; Fotopoulou C; Braicu I; Chekerov R; Schmidt SC; Pietzner K; Sehouli J
    Anticancer Res; 2011 Aug; 31(8):2603-8. PubMed ID: 21778311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
    Heiss MM; Murawa P; Koralewski P; Kutarska E; Kolesnik OO; Ivanchenko VV; Dudnichenko AS; Aleknaviciene B; Razbadauskas A; Gore M; Ganea-Motan E; Ciuleanu T; Wimberger P; Schmittel A; Schmalfeldt B; Burges A; Bokemeyer C; Lindhofer H; Lahr A; Parsons SL
    Int J Cancer; 2010 Nov; 127(9):2209-21. PubMed ID: 20473913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
    Bokemeyer C
    Expert Opin Biol Ther; 2010 Aug; 10(8):1259-69. PubMed ID: 20624115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.
    Wimberger P; Heubner M; Lindhofer H; Jäger M; Kimmig R; Kasimir-Bauer S
    Anticancer Res; 2009 May; 29(5):1787-91. PubMed ID: 19443405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.
    Sebastian M; Kiewe P; Schuette W; Brust D; Peschel C; Schneller F; Rühle KH; Nilius G; Ewert R; Lodziewski S; Passlick B; Sienel W; Wiewrodt R; Jäger M; Lindhofer H; Friccius-Quecke H; Schmittel A
    J Immunother; 2009; 32(2):195-202. PubMed ID: 19238019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma--a report of 2 cases.
    Thomaidis T; Wörns MA; Galle PR; Möhler M; Schattenberg JM
    Oncol Res Treat; 2014; 37(11):674-7. PubMed ID: 25427585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future options in the treatment of malignant ascites in ovarian cancer.
    Woopen H; Sehouli J
    Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report.
    Krawczyk M; Zimmermann S; Vidacek D; Lammert F
    Onkologie; 2012; 35(10):592-4. PubMed ID: 23038231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report.
    Pietzner K; Jäger M; Schoberth A; Oskay-Özcelik G; Kuhberg M; Lindhofer H; Sehouli J
    Med Oncol; 2012 Jun; 29(2):1391-6. PubMed ID: 21544631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catumaxomab: clinical development and future directions.
    Linke R; Klein A; Seimetz D
    MAbs; 2010; 2(2):129-36. PubMed ID: 20190561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving role of catumaxomab in gastric cancer.
    Lordick F; Ott K; Weitz J; Jäger D
    Expert Opin Biol Ther; 2008 Sep; 8(9):1407-15. PubMed ID: 18694358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.
    Ströhlein MA; Lordick F; Rüttinger D; Grützner KU; Schemanski OC; Jäger M; Lindhofer H; Hennig M; Jauch KW; Peschel C; Heiss MM
    Onkologie; 2011; 34(3):101-8. PubMed ID: 21358214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.
    Kurbacher CM; Horn O; Kurbacher JA; Herz S; Kurbacher AT; Hildenbrand R; Bollmann R
    Oncologist; 2015 Nov; 20(11):1333-41. PubMed ID: 26417039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
    Seimetz D; Lindhofer H; Bokemeyer C
    Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites.
    Barni S; Cabiddu M; Ghilardi M; Petrelli F
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):144-53. PubMed ID: 20708947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3).
    Fossati M; Buzzonetti A; Monego G; Catzola V; Scambia G; Fattorossi A; Battaglia A
    Gynecol Oncol; 2015 Aug; 138(2):343-51. PubMed ID: 26049121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.